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Certain monoclonal antibodies (mAbs) to human placental alkaline phosphatase (FLAP) block bromelain 
cleavage of a 2-kDa segment from each of the two polypeptide chains of PLAP. These mAbs also prevent 
the release of PLAP from cultured cancer cell surfaces by bromelain. Such proteolysis-blocking mAbs serve 
as tools to specifically modify the molecular topography ofcell surfaces by protease treatment. 
Alkaline phosphatase Blocking monoclonal antibody Bromelain Proteolysis 
1. INTRODUCTION 
Recently we reported that 3 out of a total of 11 
mAbs to human placental alkaline phosphatase 
(PLAP) blocked the cleavage by trypsin of a 
lo-kDa segment from PLAP [l]. We proposed 
that similar blocking antibodies to other antigens 
might be useful for proteolysis of the native 
molecule to polypeptides having desired lengths 
and for studies of the effects of proteolytic pro- 
cessing on the biological activity of a protein. The 
blocking functions of mAbs also serve as a means 
to relate the spatial arrangements of the antigenic 
sites on the native molecule. 
Now we extend that list to include the use of 
mAbs to block the release of proteins from the cell 
surface by proteolytic treatment. Several mAbs 
specific for PLAP have such an activity. They 
block the bromelain proteolytic cleavage of a 
I-kDa segment from both polypeptide chains of 
PLAP and also block the bromelain-mediated 
release of the protein from cell surfaces. Thus, 
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these mAbs serve as a means to prepare modified 
cells differing in their expression of cell-surface 
PLAP. Such a model system is useful for investiga- 
tions of the biological role of PLAP, a function 
that has thus far not been defined. By using pro- 
teolysis blocking mAbs to other antigens and ap- 
propriate proteases and lipases, this approach may 
be extended to studies of the biological functions 
of a variety of cell-surface molecules. 
2. MATERIALS AND METHODS 
2.1. Production of mAbs 
Eleven mAbs to PLAP were previously prepared 
and described [1,2]. All mAbs employed in the pre- 
sent study were either IgGl , IgG2a, or IgG2b [ 11. 
2.2. Bromelain cleavage of PLAP 
PLAP (S-variant) was purified from an in- 
dividual placenta as previously described [3]. The 
protein was labeled with ‘*?odine by the method 
of Hunter and Greenwood [4]. Bovine serum 
albumin (100 pg) was used as a carrier molecule in 
the proteolytic digestions of ‘251-PLAP (50 ng). In 
some samples the effects of various mAbs (10rg) 
on proteolysis were examined. The protein mix- 
tures were incubated with 10% bromelain (Sigma, 
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St. Louis, MO) for 30 min at 37”C, pH 6.8 in 
50 mM Hepes. Immediately after proteolysis, the 
samples were mixed with an equal volume of 10% 
2-mercaptoethanol and 2% SDS and boiled for 
3 min for evaluation in SDS-PAGE. 
2.3. Release of PLAP from the cell surface by 
bromelain 
Cells of the HeLa TCRC-1 adenocarcinoma line 
( 105) grown on 24-well tissue culture plates were in- 
cubated either with or without 1.0 ml mAb 
(50 pug/ml) in 60 ml 25 mM Hepes-buffered saline 
(pH 6.8) for 30 min at 4°C. Bromelain (100 pg/ml) 
was added to each well of the plate and further in- 
cubated for 30 min at 37°C. After proteolysis, the 
cells were no longer attached to the plate and were 
removed using a pipette. The cells were centri- 
fuged, the pellet and supernatants eparated, and 
both immediately assayed for PLAP catalytic ac- 
tivity. Substrate, p-nitrophenyl phosphate 
(10 pg/ml) at pH 9.8 in 0.1 M sodium bicarbonate 
buffer was added to the pellet and to an aliquot of 
the supernatant and the optical densities at 405 nm 
were determined after 30 min incubations. 
2.4. Observation of membrane proteins released 
from carcinoma cells by bromelain 
HeLa TCRC-1 cells (10’) were radiolabeled us- 
ing lactoperoxidase [5]. They were distributed into 
fractions and preincubated with either a 
nonspecific IgGl or PLAP-specific mAbs 
(50,~g/ml). The cells were then treated with 
bromelain (1 mg/ml) in 50 mM Hepes-saline, pH 
6.8, and the liberated and cell-bound components 
were separated by centrifugation. Each fraction 
was dissolved in 5% 2-mercaptoethanol and 1% 
SDS and boiled for 3 min prior to separation of 
components in SDS-PAGE. 
2.5. Immunoprecipitation of PLAP 
Immunoprecipitation of the supernatants 
following centrifugation of bromelain-proteolysed 
cells was performed using mAb-coated beads. 
Each supernatant (100 ~1) was incubated with 50 ,~l 
of mAb Fl 1 bound to sheep anti-mouse IgG beads 
in phosphate-buffered saline containing 5% 
bovine serum and 0.1% Tween-20. Sheep an- 
tibodies were covalently attached to methylacrylate 
beads (Dynospheres, Dyno Industrier A/S, Oslo). 
The beads were washed 3 times in phosphate- 
buffered saline and bound proteins were then 
denatured in SDS and 2-mercaptoethanol as 
described above prior to electrophoresis. 
2.6. SDS-PAGE 
SDS-PAGE in 10% polyacrylamide slab gels 
was performed as described by Laemmli [6]. After 
Coomassie blue staining to detect the standard M, 
markers, the gels were dried and subjected to 
autoradiography. 
3. RESULTS 
3. I. Monoclonal antibodies block bromelain 
cleavage of PLAP 
In a previous study we compared the specificities 
of two sets of mAbs produced against two dif- 
ferent immunizing forms of PLAP [7], either 
purified PLAP or whole HeLa TCRC-1 cells which 
express the enzyme on their surface [8]. We found 
that two out of four antibodies to purified PLAP 
(H7 and BlO) bound to a region of the molecule 
that apparently was not immunogenic when the 
immune system was presented with PLAP bound 
to HeLa TCRC-1 cells. Furthermore, these two 
mAbs bound poorly to the membranous form of 
the enzyme. However, by solubilizing the mem- 
brane with nonionic detergent or by releasing the 
enzyme from the cell surface using bromelain, the 
antigenic site for these two mAbs was exposed and 
became fully immunoreactive [7]. 
These results implied that since these mAbs (H7 
and BlO) appeared to bind at a site on PLAP hid- 
den in part by membrane components, they might 
also interfere with the proteolytic action of 
bromelain which cleaves at a site on the molecule 
near the membrane and releases PLAP from the 
cell [9]. In initial experiments we incubated ‘251- 
labeled PLAP with 11 mAbs to the antigen and ex- 
amined their ability to block cleavage by 
bromelain. The results are shown in fig. 1. Normal- 
ly, bromelain cleaves a I-kDa segment from PLAP 
[IO]. In the presence of the mAbs BlO and H7 this 
cleavage is blocked. Partial effects are observed 
with Fl 1 and C4, while the remaining 7 mAbs ap- 
pear to have no blocking activity. This experiment 
thus defines a second proteolytic site on PLAP 
distinct from the trypsin cleavage site previously 
reported that can be blocked by mAbs [l]. It is in- 
teresting to note that while H7 completely protects 
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Fig. 1. Effects of mAbs on bromelain cleavage of PLAP. 
PLAP (‘251-labeled) was incubated with the various 
mAbs, proteolyzed with bromelain, and electrophoresed 
in SDS-PAGE. Although not shown in this photograph 
PLAP migrates to the same position as the single band 
shown with BlO. 
the bromelain cleavage site, it partially blocks the 
trypsin cleavage site. Similarly, C4, which com- 
pletely blocks the trypsin cleavage site, partially 
protects the bromelain cleavage site. The overlap- 
ping effects observed with these two mAbs may be 
due to the folding of the polypeptide chain that 
positions these two cleavage sites near to one 
another in the 3-dimensional structure. This con- 
cept is further described in section 4. 
3.2. Monoclonal antibodies block the release of 
PLAP from the cell membrane by the 
protease bromelain 
The blocking effects of the mAbs observed with 
purified PLAP described above are reproduced 
when HeLa TCRC-1 cells are treated with 
bromelain as shown in fig.%. BlO is the most effec- 
tive blocking antibody, allowing for the retention 
of over 90% of the PLAP enzyme activity on the 
cells during bromelain treatment. Most of the 
15 
t 
0 S”pernatant 
n cell petlet 
F6 GlO E5 82 C4 A3 “5 H7 Fll DIO , 
I 
no At, 
Fig.2. Effects of mAbs on the release of PLAP from the 
surface of HeLa TCRC-1 adenocarcinoma cells by 
bromelain. PLAP catalytic activity was monitored 
immediately following proteolysis using p-nitrophenyl- 
phosphate as substrate. 
other antibodies, GlO, B2, E5, F6, H5 and C4, 
have no blocking activity. Partial blocking activity 
is observed with H7 and Fll as expected from the 
results shown in fig.1, and also by DlO. The latter 
antibody does not block bromelain cleavage of 
purified PLAP. Furthermore, C4, which appears 
to partially block the cleavage of the free enzyme, 
has no effect on membrane-bound PLAP. The dif- 
ferences observed with these two mAbs, DlO and 
C4, may be due to interference by other molecules 
in the membrane. Since the most complete block- 
ing effect by the mAbs was observed with BlO, the 
effects of that mAb were explored further. 
3.3. Selective retention of PLAP on the plasma 
membrane during proteolysis using a 
blocking monoclonal antibody 
To examine molecular profiles of the cell surface 
of HeLa TCRC-1 cells before and after bromelain 
treatment, the cells were surface labeled with 
‘?odine employing lactoperoxidase [5]. After they 
were radiolabeled, the cells were incubated either 
with a nonspecific antibody, F6 which does not 
block bromelain proteolysis, or BlO which does. 
The cells were then incubated with bromelain for 
30 min and centrifuged. The supernatants and cell 
pellets were electrophoresed in SDS-PAGE under 
reducing and denaturing conditions. The results 
are shown in fig.3. 
The prominent band at 67 kDa (fig.3) which is 
present on the BlO preincubated cells is absent in 
the cell pellet of the other two incubations. Con- 
cordantly in the supernatants of the latter there ap- 
pears a band at 65 kDa that is absent from the 
supernatant of the BlO preincubated cells. The 
65-kDa band is proteolysed PLAP resulting from 
bromelain cleavage of a 2-kDa segment from both 
polypeptide chains [9]. This is confirmed by im- 
munoprecipitation of proteins in the three super- 
natants using mAb Fll coupled to sheep anti- 
mouse IgG on Dynosphere monodisperse polymer 
particles (Dyno Industrier A/S, Oslo) (fig.4). This 
antibody binds at a site distinct from the sites for 
F6 and BlO and, therefore, can bind simultaneous- 
ly to the molecule [2,7]. No precipitable material is 
observed in the BlO preincubated material in- 
dicating that PLAP was not liberated from the cell 
surface in that case. 
Other than the 67- and 65-kDa bands of PLAP, 
no apparent differences are observed among the 
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Fig.3. Autoradiograph of SDS-PAGE of iodinated cell 
surface components in the supernatants and the cell 
pellets of mAb-pretreated, bromelain proteolyzed cells. 
The control mAb used was nonspecific IgGl. 
three preparations, indicating that the modified 
cells in each experiment are otherwise identical. It 
is interesting to note that not all of the radiolabeled 
proteins are liberated from the membrane using 
bromelain. 
The removal of PLAP from the membrane by 
bromelain is not permanent. Previously it was 
shown that within 55 min after proteolysis, PLAP 
begins to reappear at the cell surface [lo]. Thus, 
for use in the investigation of the biological role of 
PLAP, the modified cells must be used immediate- 
ly after preparation. Over 90% of the treated cells 
failed to absorb trypan blue, indicating that they 
were largely impermeable to molecules not actively 
transported into the cells. Therefore, since many 
of the cell surface proteins remain on the mem- 
brane after bromelain proteolysis (fig.3), it is likely 
that these modified cells will retain many of the 
biological activities of the intact cell. Furthermore, 
27K-‘. ,,.,i 
Fig.4. Immunoprecipitation of the supernatants from 
bromelain proteolyzed, iodinated HeLa TCRC-1 cells 
using mAb Fll and sheep antibodies to mouse IgG 
covalently attached to methylacrylate beads. The cells 
were preincubated with the indicated mAbs prior to 
proteolysis. 
most of the cellular architecture necessary for 
those functions is likely to remain intact or at least 
be more similar to the native state than that 
observed in reconstituted vesicles. 
4. DISCUSSION 
In a previous report we described a set of mAbs 
to PLAP (C4, ES, and F6) that protected the only 
trypsin cleavage site on each of the two PLAP 
polypeptide chains of the native protein [l]. The 
present study identifies a different proteolytic 
cleavage site on each polypeptide chain recognized 
by bromelain that can be protected by a second set 
of mAbs (BIO and H7). 
It has been suggested from tandem proteolytic 
digests of trypsin and bromelain that these two 
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proteases recognize sites at opposite ends of the 
polypeptide chain [l 11. The fact that each of two 
different sets of mAbs recognizing distinct 
epitopes [7] protect different sites from proteolytic 
cleavage supports this conclusion. It is possible 
that the amino and carboxyl terminal ends of each 
polypeptide chain are folded near to one another in 
the 3-dimensional structure of PLAP, as is the case 
with E. coli alkaline phosphatase [12]. This would 
explain the partially overlapping proteolysis- 
blocking effects on both trypsin and bromelain 
cleavage observed with the mAbs C4 and H7 
described in section 3. 
Of potential importance to cell-surface 
biochemistry is the description in this report of a 
novel means to engineer specific topographical 
changes on cells using mAbs that block pro- 
teolysis. In our model system, cultured cancer cells 
were modified such that they either did not have 
PLAP on their surface, or they expressed that en- 
zyme with an attached monoclonal antibody. 
Bromelain was used as the protease to remove cell 
surface proteins and its proteolytic attack on 
PLAP was specifically blocked by employing a 
mAb to PLAP that binds near to the bromelain 
cleavage site. 
This approach may have an advantage over 
traditional cell models where membrane com- 
ponents are reconstituted into membrane vesicles. 
The removal of molecules from the cell by pro- 
teases is not likely to alter the relative orientations 
of remaining components left on the membrane. 
Thus, interactions that are required for the 
biological activity of a molecule are more likely to 
occur in this model system than in reconstituted 
vesicles. 
It is likely that antibodies similar to those 
presented here which block bromelain proteolysis 
of other cell surface proteins can be prepared. Fur- 
thermore, other enzymes that remove molecules 
specifically from the cell surface also exist. For ex- 
ample, phosphoinositol-specific phospholipase C 
has been shown to release alkaline phosphatases 
from cells [13,14]. If mAbs block the action of 
other proteases or lipases, each of which releases 
different components from the membrane, it will 
be possible to prepare a variety of short-term 
modified cells having different molecular reper- 
toires expressed on their surface. This would fur- 
ther increase the application of the approach 
described here in studying cell-surface macromole- 
cules . 
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